Candice Monson
Professor of Psychology and Director of the IMPACT Lab at Toronto Metropolitan University
Data updated
Research Footprint
Candice Monson appears in 5 tracked papers (2019–2026), most studied alongside MDMA and Psilocybin, across Depressive Disorders, PTSD and Anxiety Disorders.
Most-cited paper: Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example (91 citations).
Frequent co-authors: Anne Wagner, Michael Mithoefer and Ann Mithoefer.
Background & Research
Candice M. Monson, PhD, is a Professor of Psychology at Toronto Metropolitan University and Director of the IMPACT Lab (Investigating Methods to Prevent, Assess and Care for Trauma). Her research focuses on traumatic stress, intimate relationships, cognitive-behavioral therapies, and couple-based interventions for PTSD, and she has helped develop and disseminate cognitive-behavioral conjoint therapy for PTSD. She previously held research and faculty appointments in U.S. trauma and psychiatry settings, including work with the National Center for PTSD and Boston University School of Medicine.
Key Impact
A leading PTSD and couples-therapy researcher whose work extends into MDMA-assisted psychotherapy and psychedelic trial methodology.
Collaboration Network
13 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Candice Monson is associated with.
Toronto Metropolitan University
academicToronto Metropolitan University (formerly Ryerson University) is a public research university in downtown Toronto, Canada. Its psychology, health science, and social science researchers participate in clinical studies on psychedelic-assisted therapy, with faculty investigating the effects of psilocybin and other compounds on mental health outcomes in clinical and community populations.
View stakeholder →MAPS
nonprofitMAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
View stakeholder →